The search for new precision therapies in infectious diseases where the usual antimicrobials are losing effectiveness, and for diseases of molecular origin (eg, conformational diseases) requires identifying and analyzing the causes of the problem and creating multidisciplinary teams that allow following the pathway that converts a newly identified candidate molecule into a drug.
LINEAS DE INVESTIGACION
- To identify stages of formation of bacterial biofilm susceptible for being blocked by antimicrobial agents and to develop knowledge about the composition of biofilms.
- To identify compounds to encourage or produce the disintegration of the biofilm or to have a synergistic effect with the antimicrobials against microorganisms in biofilm.
- To identify microbiota profiles in specific diseases and in patients to modulate it and to reverse the imbalance in disease / health.
- To improve bactericidal compounds against Helicobacter pylori, one of the largest known pandemics, especially for macrolide-resistant strains.
- To develop antimicrobial compounds against multiresistant strains of Escherichia coli, Staphylococcus aureus, Enterococcus or Clostridium difficile, among others.
- To develop new compounds for molecular therapies against amyloid diseases and non-aggregative conformational diseases.
PRESENTATION OF THE CONSORTIUM
This consortium gathers basic research teams from the universities of Lleida, Zaragoza, Public of Navarre and La Rioja (microbiologists, biochemists and molecular biologists experts in the study and treatment of infectious diseases and diseases of a molecular origin and in discovery and development of new bioactive compounds) and clinical groups with experience in translational research, all groups with proven interaction with companies in this sector. Also, a company with wide experience in the biotechnological use of wild or recombinant microorganisms participates in the consortium. The general objective is to contribute to the development of new therapies of precision (personalized therapies) that allow to choose the drug most appropriate to the patient’s genetic idiosyncrasy and, if it is applicable, to the nature of the specific microorganism in the infectious process.
MEMBERS OF THE CONSORTIUM
IP: Javier Sancho (Universidad de Zaragoza – BIFI)
Universidad de La Rioja: Carmen Torres
Universidad Pública de Navarra: Iñigo Lasa
Universidad de Lleida: Gemma Bellí
Universidad de Zaragoza: Angel Lanas
Université de Toulouse –Alain Bousquet-Melou.
Recombina S.L.- empresa biotecnológica de ingeniería genética
- Antimicrobial resistance
- New antimicrobials
- Metabolic diseases
- Personalized treatments
- Bioactive compounds